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The Optimal Intensity of Vitamin K
Antagonists in Patients With
Mechanical Heart Valves: A Meta-analysis
I enjoyed the article by Vink et al. (1), which again revisits
an old and most important clinical chestnut, but I have
serious misgivings about their conclusions. Some years ago,
we did a detailed and comprehensive analysis of 1,134
patients who had received St. Jude prosthetic valve(s) over a
13-year period (2). The follow up was 100% complete—
4,936 patient years—and the study had a 60% post-mortem
examination rate for early deaths.
The recommendation we made as the result of our
analysis, namely that the INR should be kept between 2.5
and 3.0, is at complete variance with that of the authors. I
believe that the problem arises from the fact that the target
international normalized ratio (INR) range on which the
authors focused may have no bearing whatsoever on the
INR at the actual time of the anticoagulant-related compli-
cation. In contrast, we based our recommendations on the
INR measured at the actual time of the anticoagulant-related
complication, which we had in 88% and 58% of the major
thromboembolic and hemorrhagic complications, respec-
tively. Furthermore, in a more recent study (3), we found
that at any given time 21.8% to 32.5% of patients were
outside the target INR set for them; indeed, other authors
have found an even greater number of patients (up to 52%)
outside the target INR range (4).
It is essential therefore to base any recommendation
regarding anticoagulation on an analysis of INR readings at
the actual time of the anticoagulant-related complications
rather than the target INR range, which is the ideal rather
than the reality.
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Anticoagulation Management
of Patients With Prosthetic Valves
As authors of previous European guidelines on anticoagu-
lation of patients after valve surgery and as members of a
committee currently revising those guidelines, we are con-
cerned to read the paper of Vink et al. (1) Their recom-
mendation that all patients should be managed with an
international normalized ratio (INR) of 3.0 to 4.5 reverses
current trends to individualize antithrombotic management
for each patient based on an assessment of their particular
thromboembolic risk (2–4). Although having a “one size fits
all” approach to anticoagulation management may have
advantages for anticoagulation clinics, this approach will not
benefit individual patients who may be exposed to the risks
of unnecessarily high anticoagulation.
Their meta-analysis raises several concerns. First, meta-
analysis is a technique for amalgamating data from random-
ized controlled trials (RCT) that have used the same
methodology, not observational studies with different meth-
odology. Second, reported thromboembolic rates are heavily
influenced by definitions, data collection methods (prospec-
tive vs. retrospective), size and length of study, patient risk
factors, concomitant surgery, and type of prosthesis (5,6).
Other than the prosthetic type, these factors are not
mentioned. Valve thrombosis rates are influenced by the
number of patients who experienced anticoagulation inter-
ruption, to which most cases are related (7). Third, we
question the use of target INRs rather than achieved INRs.
Many events occur when the INR is outside the target
range.
Fourth, retrospective conversion of prothrombin time
ratios to INR has the potential to introduce huge errors. In
American studies, it is highly unlikely that a single throm-
boplastin reagent would have been used for all patients in
the study (8).
Finally, there is a lack of acknowledgment of the five
published RCTs comparing different anticoagulation inten-
sity (9–13). Although most of these RCTs have limited
applicability because of their methodologies, all reached the
conclusion that a higher intensity of anticoagulation did not
reduce the incidence of thromboembolism. Four RCTs
showed a higher incidence of bleeding with higher intensity
anticoagulation. The only RCT not to show this effect used
overlapping INR ranges and did not record events in the
first three months (13).
Although Vink et al. (1) acknowledge that high-intensity
anticoagulation results in a higher incidence of bleeding,
they appear to minimize this danger. Use of a higher range
of INR, 3.0 to 4.5, for all patients imposes an imperative for
extremely tight INR control. High variability of INR, with
30% of INRs outside the range 2.0 to 4.0, is the strongest
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predictor of reduced survival after valve replacement (14).
Furthermore, thromboembolic and bleeding events are not
equivalent in terms of mortality risk. The one-year survival
after ischemic stroke is about 80%, whereas the one-year
survival after intracerebral hemorrhage is only about 20%
(15).
The paper of Vink et al. (1) reinforces the view of the
Dutch Thrombosis Service since the mid-1980s that all
mechanical valve patients should have an INR of 3.0 to 4.5,
(16) However, it is scientifically unsound in its methodol-
ogy, ignores evidence for a contrary view, including RCTs
and current guidelines (2,4,17), and takes a big step back-
ward from the modern practice that is based on individual
risk stratification and risk-adjusted intensity of anticoagu-
lation. We believe that their recommendations should not
be followed.
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REPLY
We appreciate the comments regarding our article (1). Dr.
Takkenberg and colleagues have calculated mortality rates
of the thromboembolic and bleeding complications and
found no differences between high-intensity and low-
intensity therapy with vitamin K antagonists. Unfortu-
nately, only approximately 50% of the included studies
reported on mortality rates. As a result, the mortality event
rate is too low to draw any statistically confident conclusion.
Therefore, it remains uncertain whether the results of this
small number of studies would be representative for the total
mortality rate of all studies analyzed in our meta-analysis.
Dr. O’Kane raised an important point about the target
international normalized ratio (INR). We agree that it is
more sound to evaluate the achieved INR rather than the
target INR. However, as already mentioned in our article,
most reports used for our analysis were based on an
intention-to-treat INR range. Furthermore, Dr. O’Kane
recommends an INR between 2.5 and 3.0 based on a
single-center observational study, which unfortunately lacks
information on the time spent in the target range and the
achieved INR. In addition, a part of the study population in
this study received dipyramidole in combination with vita-
min K antagonists, which increased the risk of bleeding
complications (2).
Drs. Butchart and Gohlke-Bärwolf are confused when
they state that meta-analyses can be performed only on
randomized controlled trials. It should be clarified that
meta-analysis is a statistical method defined as the quanti-
tative analysis of two or more independent studies to
integrate the findings. Studies used for meta-analysis can
vary from randomized trials, non-randomized trials, or
observational studies, and even from more than one of these
types of studies (3).
Furthermore, they postulate that the reported thrombo-
embolic rates are influenced by definitions, data collection
methods, and patient characteristics. In our study, all events
were analyzed according to the guidelines for reporting
morbidity and mortality after cardiac valvular operations of
Edmunds et al. (4), which minimize the potential for bias.
Mean age at valve implantation and gender did not differ
between the groups. Other characteristics were not specified
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